Clozapine and Risperidone: Refining and Extending Their Use

Buckley, Peter F.; Schulz, S. Charles

doi:10.3109/10673229609030543

Cited by 9 publications

(5 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The selective serotonin reuptake inhibitors (SSRIs) have often been used as an augmentation strategy to enhance efficacy of both typical (Christison et al 1991) and atypical (Buckley and Schulz 1996) antipsychotic medications. The therapeutic rationale is to enhance treatment response to negative and positive residual symptoms.…”

Section: Augmentation Therapies: Reviewing the Literaturementioning

confidence: 99%

When Symptoms Persist: Clozapine Augmentation Strategies

Buckley

Miller

Olsen

et al. 2001

Schizophrenia Bulletin

110

View full text Add to dashboard Cite

Recent data and clinical experience confirm that, in spite of superior efficacy for treatment-refractory schizophrenia, a substantial proportion of patients receiving clozapine will continue to experience disabling symptoms. Optimizing clozapine monotherapy is the first step in the management of "clozapine nonresponders." Described here is a synthesis of the available literature on the range and efficacy of clozapine augmentation strategies that may be used when monotherapy fails. Treatment options include adjunctive antipsychotic medications, mood stabilizers, selective serotonin reuptake inhibitors, glycinergic agents, and electroconvulsive therapy. The evidence favoring one augmentation strategy over another is lacking; overall, adjunctive therapy is associated with only modest clinical improvement. Moreover, case series and open-labeled clinical trials dominate the extant literature, and there is a dearth of double-blind trials comparing these augmentation agents. Current systematic efforts to enhance the treatment of these patients with adjunctive therapies are worthy of being studied in carefully conducted clinical trials.

show abstract

Section: Augmentation Therapies: Reviewing the Literaturementioning

confidence: 99%

When Symptoms Persist: Clozapine Augmentation Strategies

Buckley

Miller

Olsen

et al. 2001

Schizophrenia Bulletin

110

View full text Add to dashboard Cite

show abstract

“…In recent years, investigators have examined the effects of new atypical antipsychotic medications, such as clozapine, on the negative, as well as the positive, symptoms of schizophrenia; effects on cognitive correlates of the disorder have also been examined. Despite equivocal evidence for such effects (Bond & Meyer, 1999;Buckley & Schulz, 1996), people have become hopeful that broader effects of the new medications might lead to improved functioning in areas such as independent living and employment. If medications could alleviate negative symptoms such as lack of persistence at work or school, then one might intuitively expect that they would allow more people with schizophrenia to work.…”

Section: Basic Schizophrenia Research Approachmentioning

confidence: 99%

Understanding the employment rate of people with schizophrenia: Different approaches lead to different implications for policy.

Blyler¹

2003

Principles of Experimental Psychopathology: Essays in Honor of Brendan A. Maher.

View full text Add to dashboard Cite

One of the tragedies of modern academic psychology is that the pressure to publish and the need to prove that psychology is, in fact, a real science can lead to the objectification of human beings, including both the "subjects" one is studying as well as the students and colleagues with whom one works. As a student of history, Brendan Maher is confident in the well-established scientific roots of experimental psychopathology. This allows him to convey the importance of objective, quantifiable measurement, even while respecting the validity of internal subjective experience. Thus, in his research studies, he never loses sight of how the participants are experiencing the symptoms that he is so carefully measuring and analyzing. In his teaching, he does not allow his desire to convey specific information to dominate over the humor and storytelling that are so important to motivate students to learn. In his mentorship, he does not confuse his own research interests with those of his student. And in his administrative role, he manages to convey compassion and warmth simultaneously with clarity of purpose and ethical integrity. Although I have learned much from the direct teaching and writing of Professor Maher, the greatest lesson comes from observing him as a role model. The making of a great scientist, I have learned, requires not only the ability to generate creative ideas of one's own but also an inherent respect for the ideas and subjective experiences of others.I was a graduate student of Maher's from 1988 to 1994. While I was at Harvard, I worked with him on developing a simple method of assessing motor disorder in The Employment Intervention Demonstration Program (EIDP) is a multisite collaboration among eight research demonstration sites, a coordinating center, and the Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Mental Health Services (CMHS), which funds the initiative (Public Health Service Cooperative Agreement SM51820). The data presented are from analyses conducted by the Coordinating Center at the University of Illinois at Chicago using preliminary multisite data sets. The publication policy of EIDP does not allow inclusion of final cross-site data in the chapter at this time; all data presented are strictly preliminary. Updated information on the study can be found at the EIDP website: http://www.psych.uic.edu/eidp. This article was written in a personal capacity and does not necessarily represent the opinions of CMHS, SAMHSA, the U.S. Department of Health and Human Services, the federal government, or EIDP collaborating partners.

show abstract

“…Whitten and Ruehter have reported hyponatremia without polydipsia with risperidone [3]. Many studies [4][5][6][7][8] including that by Kruse et al . [9] have found risperidone beneficial in polydipsia.…”

Section: Cerebellar Ataxia With Intravenous Valproate and Haloperidolmentioning

confidence: 99%

Responsible Regulation of Psychiatric Practice

Dawson¹

2002

Aust N Z J Psychiatry

View full text Add to dashboard Cite

A major drug of abuse today is 3,4-Methylenedioxymethamphetamine (MDMA or 'ecstasy'). Serious medical complications and neurotoxicity are known to be caused from its uncontrolled use, but most long-term effects are still unkown. Neuropsychological studies show cognitive deficiencies in chronic users [1].In March 1999, a 22-year-old man with a 3 year history of drug abuse was admitted to our detoxification ward. Childhood and education were without major complications. He had been taking cannabis since 1996 and 'ecstasy' tablets almost daily since 1997. He documented in his diary the ingestion of more than 350 'ecstasy' tablets in 18 months (up to eight tablets at

show abstract

Clozapine and Risperidone: Refining and Extending Their Use

Cited by 9 publications

References 79 publications

When Symptoms Persist: Clozapine Augmentation Strategies

When Symptoms Persist: Clozapine Augmentation Strategies

Understanding the employment rate of people with schizophrenia: Different approaches lead to different implications for policy.

Responsible Regulation of Psychiatric Practice

Contact Info

Product

Resources

About